Combination of the dual PIM/PI3-kinase inhibitor IBL-202 and venetoclax is effective in diffuse large B-cell lymphoma.

abstract：:Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymph...

journal_title：Leukemia & lymphoma

authors： Perz J,Topaly J,Fruehauf S,Hensel M,Ho AD

更新日期：2002-01-01 00:00:00

abstract：:The insulin-like growth factor (IGF) system regulates proliferation and differentiation of hematopoietic cells. IGFs exert their effects through specific receptors on growing and differentiating blood cells as they emerge from their small pool of ancestral stem cells. The IGF system is complex as both stimulating and ...

journal_title：Leukemia & lymphoma

authors： Zumkeller W

更新日期：2002-03-01 00:00:00

abstract：:The relationship between histopathologic characteristics and treatment outcomes in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-based immunochemotherapy needs re-evaluation. Patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednis...

journal_title：Leukemia & lymphoma

authors： Hong J,Park S,Park J,Kim HS,Kim KH,Ahn JY,Rim MY,Jung M,Sym SJ,Cho EK,Shin DB,Lee JH

更新日期：2011-10-01 00:00:00

abstract：:Primary non-Hodgkin's lymphoma of bone is uncommon and usually manifests clinically as localized bone pain. Here we report a woman who presented with hypercalcemic crisis and extensive investigation revealed a primary multifocal lymphoma of bone. The course of the disease was very aggressive and despite intensive supp...

journal_title：Leukemia & lymphoma

authors： Evron E,Goland S,Klepfish A,Malnick SD,Sokolowski N,Sthoeger ZM

更新日期：1999-06-01 00:00:00

abstract：:INHBA (inhibin βA), a subunit of a ligand of the transforming growth factor-β superfamily, is known to play diverse roles in various solid tumors. However, its role in hematologic malignancies remains unexplored. Here, we investigated the function of INHBA in diffuse large B-cell lymphoma (DLBCL). Both mRNA and protei...

journal_title：Leukemia & lymphoma

authors： Jiang L,Si T,Yu M,Zeng X,Morse HC 3rd,Lu Y,Ouyang G,Zhou JX

更新日期：2018-05-01 00:00:00

abstract：:Follicular lymphoma (FL) is characterized by an initial response to treatment with inevitable relapse. We evaluated chemoimmunotherapy resistance (CIR resistance) including transformation. We identified patients who received rituximab combination therapy for symptomatic FL. CIR resistance was defined as disease progre...

journal_title：Leukemia & lymphoma

authors： Mozessohn L,Cheung MC,Crump M,Buckstein R,Berinstein N,Imrie K,Kuruvilla J,Piliotis E,Kukreti V

更新日期：2014-11-01 00:00:00

abstract：:Myeloproliferation, myeloaccumulation (decreased apoptosis), inflammation, bone marrow fibrosis and angiogenesis are cardinal features of the Philadelphia-negative chronic myeloproliferative neoplasms: essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). Histone deacetylases (HDACs) ...

journal_title：Leukemia & lymphoma

authors： Skov V,Larsen TS,Thomassen M,Riley CH,Jensen MK,Bjerrum OW,Kruse TA,Hasselbalch HC

更新日期：2012-01-01 00:00:00

abstract：:Endoglin (CD105) is a component of the transforming growth factor-beta (TGF-beta) receptor (TGF-betaR) complex. Together with betaglycan, CD105 is considered as a TGF-betaR accessory molecule (also called TGF-betaRIII), but its functions in the receptor-ligand interactions are still poorly understood. A small subset o...

journal_title：Leukemia & lymphoma

authors： Pierelli L,Bonanno G,Rutella S,Marone M,Scambia G,Leone G

更新日期：2001-11-01 00:00:00

abstract：:Chronic lymphocytic leukemia (CLL) is a neoplastic disorder of mature B lymphocytes. While traditionally treated with combinations of chemoimmunotherapy, the therapeutic options for CLL have expanded in recent years with the emergence of novel oral agents, such as the Bruton tyrosine kinase inhibitor ibrutinib, that a...

journal_title：Leukemia & lymphoma

authors： Piggin A,Bayly E,Tam CS

更新日期：2017-06-01 00:00:00

abstract：:There is insufficient information on the characteristics of chronic lymphocytic leukemia (CLL) in Latin American patients. Immunoglobulin variable-region heavy-chain (IGVH) gene usage and mutation status and prognostic factors were investigated in patients resident in Venezuela. The most frequently used IGVH family ge...

journal_title：Leukemia & lymphoma

authors： Marquez ME,Deglesne PA,Lopez JL,Da Costa O,Borrego M,Hernández M,Muller A,Ajchenbaum-Cymbalista F,Romano E

更新日期：2012-02-01 00:00:00

abstract：:Acute graft versus host disease (aGVHD) was first described by Barnes et al. in 1962, who reported a 'secondary disease' in mice after irradiation and infusion of allogeneic spleen cells. The disease manifested as fatal diarrhea and skin abnormalities. They postulated that aGVHD resulted from introducing immunological...

journal_title：Leukemia & lymphoma

authors： Gergis U,van Besien K

更新日期：2019-09-01 00:00:00

abstract：:Syndecan-1 is a transmembrane proteoglycan expressed on the surface of tumor cells of various origins including myeloma, Hodgkin's disease, and certain human immunodeficiency virus (HIV) associated lymphomas. Functional studies in myeloma reveal that syndecan-1 may act as a multifunctional regulator of cell behavior i...

journal_title：Leukemia & lymphoma

authors： Dhodapkar MV,Sanderson RD

更新日期：1999-06-01 00:00:00

abstract：:Severe myelosuppression is one of the major adverse effects of Idarubicin (IDA). Especially, after two sequential therapy courses, IDA showed a stronger myelosuppression than after the first course. IDA was metabolized in liver by carbonyl reducing enzymes (CRE) to its 13-OH metabolite, idarubicinol(IDAol),which is mo...

journal_title：Leukemia & lymphoma

authors： Yamashita T,Fukushima T,Ueda T

更新日期：2008-04-01 00:00:00

abstract：:Eighteen patients (pts) with myelodysplastic syndrome (MDS) were treated with thymopentin (TP) (50 mg subcutaneously for 5 days) and recombinant interferon alpha 2a (rIFN alpha 2a) (3 MU/m2 subcutaneously on the sixth day); the courses were delivered every week. Moreover those pts with > or = 10% blasts in the bone ma...

journal_title：Leukemia & lymphoma

authors： Venditti A,Scimò MT,del Poeta G,Buccisano F,Stasi R,Mastino A,Grelli S,Favalli C,Garaci E,Papa G

更新日期：1995-01-01 00:00:00

abstract：:Autologous stem cell transplantation (ASCT) has been used as treatment for immunoglobulin light-chain (AL) amyloidosis for over two decades with improving outcomes; however, the majority of patients are not candidates for this therapy at diagnosis. Novel agents such as immunomodulatory drugs, proteasome inhibitors, an...

journal_title：Leukemia & lymphoma

authors： Sidiqi MH,Gertz MA

更新日期：2019-02-01 00:00:00

abstract：:We applied two-step multicolor flow cytometry (FCM) for circulating lymphoma cells in the blood of 20 patients with angioimmunoblastic T-cell lymphoma (AITL) and confirmed neoplastic T-cells in all. Eleven exhibited dim expression of CD3 and 7 lost its expression. The proportion of CD10+ lymphoma cells ranged widely f...

journal_title：Leukemia & lymphoma

authors： Hayashida M,Maekawa F,Chagi Y,Iioka F,Kobashi Y,Watanabe M,Ohno H

更新日期：2020-10-01 00:00:00

abstract：:The association of chronic lymphocytic leukemia (CLL) with essential thrombocythemia (ET) is an extremely rare event and until now 3 patients with such coexistence have been reported in the literature. We report a 77-year-old white woman in whom these two disorders were diagnosed concomitantly on the basis of peripher...

journal_title：Leukemia & lymphoma

authors： Robak T,Urbańska-Ryś H,Góra-Tybor J,Wawrzyniak E,Korycka A,Bartkowiak J,Kordek R,Polliack A

更新日期：2003-08-01 00:00:00

abstract：:The objective of this study was to assess the impact of the primary prophylaxis of granulocyte colony-stimulating factor (G-CSF) in the management of childhood B-cell non-Hodgkin lymphoma (B-NHL). Patients with advanced-stage mature B-NHL were randomized to receive prophylactic G-CSF (G-CSF+) or not receive G-CSF (G-C...

journal_title：Leukemia & lymphoma

authors： Tsurusawa M,Watanabe T,Gosho M,Mori T,Mitsui T,Sunami S,Kobayashi R,Fukano R,Tanaka F,Fujita N,Inada H,Sekimizu M,Koh K,Kosaka Y,Komada Y,Saito AM,Nakazawa A,Horibe K,lymphoma committee of the Japanese Pediatric Leuke

更新日期：2016-07-01 00:00:00

abstract：:The induction of apoptosis following topoisomerase inhibitors proceeds in at least three distinct steps: (1) induction of cleavable complexes (potentially lethal damage), (2) topoisomerase-induced DNA damage, and (3) a presently unknown sequence of events that must either lead to cell cycle arrest (G2-block, different...

journal_title：Leukemia & lymphoma

authors： Solary E,Bertrand R,Pommier Y

更新日期：1994-09-01 00:00:00

abstract：:Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphomas (NHL) characterized in almost all cases by the chromosomal translocation t(11;14)(q13;q32) and nuclear cyclin D1 overexpression. Most patients present with advanced stage disease, often with extranodal dissemination, and typically pursue an...

journal_title：Leukemia & lymphoma

authors： Weigert O,Unterhalt M,Hiddemann W,Dreyling M

更新日期：2009-12-01 00:00:00

abstract：:In classical reduced-intensity conditioning (RIC) regimens, including the fludarabine and busulphan (BF) combination, sirolimus and tacrolimus (SIR-TAC) as graft vs host disease (GVHD) prophylaxis has shown acceptable results. The outcomes of SIR-TAC in a more intense RIC regimen as Thiotepa-fludarabine-busulfan (TBF)...

journal_title：Leukemia & lymphoma

authors： Fox ML,García-Cadenas I,Pérez AM,Villacampa G,Piñana JL,Ortí G,Montoro J,Roldán E,Bosch Vilaseca A,Martino R,Salamero O,Saavedra S,Hernandez-Boluda JC,Esquirol A,Sierra J,Sanz J,Solano C,Bosch F,Barba P,Valcarcel D

更新日期：2020-08-01 00:00:00

abstract：:The soluble Interleukin-2 Receptor (sIL-2R) serum levels were assessed in 42 patients with Hairy-Cell Leukemia (HCL) at diagnosis and after alpha-Interferon therapy and correlated with spleen size, peripheral hematological values, hairy cell index (HCI) and clinical response. Serum sIL-2R levels were significantly inc...

journal_title：Leukemia & lymphoma

authors： Lauria F,Rondelli D,Raspadori D,Zinzani PL,Benfenati D,Pileri S,Sabattini E,Tura S

更新日期：1992-05-01 00:00:00

abstract：:A two-year-old girl presented with a 3-month history of generalized pruritus. One week before hospitalization she developed a superior vena cava syndrome and obstruction of the upper airways. Clinical and laboratory findings included generalized lymphadenopathy, a mediastinal mass compressing the tracheal lumen to the...

journal_title：Leukemia & lymphoma

authors： Vècsei A,Attarbaschi A,Krammer U,Mann G,Gadner H

更新日期：2002-09-01 00:00:00

abstract：:We have analyzed the co-expression of the bcr-abl and HoxA9 genes in the follow-up of patients with chronic myeloid leukemia (CML). In the present work we measured the HoxA9 and bcr-abl gene expression in sequential samples. In all patients, bcr-abl and HoxA9 were expressed at detectable levels in every sample. When t...

journal_title：Leukemia & lymphoma

authors： Tedeschi FA,Cardozo MA,Valentini R,Zalazar FE

更新日期：2010-05-01 00:00:00

abstract：:The capacity to generate effective dendritic cells (DC) from adult acute lymphoblastic leukemia (ALL) patients in complete remission (CR) and off-therapy was investigated. Monocyte-derived DC cultured in the presence of granulocyte-macrophage colony-stimulating factor, interleukin (IL)-4 and tumor necrosis factor (TNF...

journal_title：Leukemia & lymphoma

authors： Maggio R,Peragine N,Calabrese E,De Propris MS,Intoppa S,Della Starza I,Ariola C,Vitale A,Foà R,Guarini A

更新日期：2007-02-01 00:00:00

abstract：:Morbidity, mortality and discomfort related to gastrectomy has led some investigators to treat patients with stage I-II primary gastric high-grade lymphoma (PGL) with a conservative strategy. Here we report a retrospective series of 21 patients with PGL treated with primary chemotherapy alone or followed by radiation ...

journal_title：Leukemia & lymphoma

authors： Ferreri AJ,Cordio S,Ponzoni M,Villa E

更新日期：1999-05-01 00:00:00

abstract：:A clinical case of patient with a simultaneous gastrointestinal stromal tumors (GIST) and MALT lymphoma in relapse is presented. Simultaneous treatment with imatinib mesylate and rituximab was given, yielded response for both tumors and was well tolerated. ...

journal_title：Leukemia & lymphoma

authors： Bompas E,Velay B,Blay JY

更新日期：2004-11-01 00:00:00

abstract：:A leukemia-associated CD9 glycoprotein antigen released into the extracellular milieu from acute lymphoblastic leukemia cells has been detected using a unique lectin-monoclonal antibody immunoassay. It has been demonstrated that the release of CD9 antigen is an active process and is associated with active cell growth....

journal_title：Leukemia & lymphoma

authors： Komada Y,Sakurai M

更新日期：1994-02-01 00:00:00

abstract：:The standard CHOP regimen may cure 30-40% of patients with advanced aggressive non-Hodgkin's lymphoma (ANHL). Mitoxantrone is an anthracenedione, which is active in NHL and its toxicity profile may be more favorable than doxorubicin with respect to alopecia, mucositis and cardiotoxicity. This study was designed to com...

journal_title：Leukemia & lymphoma

authors： Pangalis GA,Vassilakopoulos TP,Michalis E,Roussou P,Vrakidou E,Repousis P,Angelopoulou MK,Siakantaris MP,Korantzis J,Symeonidis A,Grigorakis V,Stefanoudakis E,Stamatellou M,Bourantas KL,Kalmantis T,Christopoulos G,Kokkini

更新日期：2003-04-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is infrequent in patients with human immunodeficiency virus (HIV) infection. Among AML, acute promyelocytic leukemia (APL) has been rarely described in such patients, with only one case being published. We report a 30 years-old intravenous drug abuser HIV-infected male with APL who attaine...

journal_title：Leukemia & lymphoma

authors： Calvo R,Ribera JM,Battle M,Sancho JM,Granada I,Flores A,Millá F,Feliu E

更新日期：1997-08-01 00:00:00